Merck & Co., Inc. (TSX:MRK)

Canada flag Canada · Delayed Price · Currency is CAD
26.76
+0.60 (2.29%)
At close: Feb 4, 2026
17.16%
Market Cap401.66B +15.0%
Revenue (ttm)89.14B +1.3%
Net Income25.03B +6.6%
EPS9.98 +8.0%
Shares Outn/a
PE Ratio16.05
Forward PE22.95
Dividend0.74 (2.78%)
Ex-Dividend DateDec 15, 2025
Volume4,026
Average Volume5,485
Open26.17
Previous Close26.16
Day's Range26.17 - 27.02
52-Week Range16.84 - 27.02
Betan/a
RSI73.62
Earnings DateFeb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B... [Read more]

Sector Healthcare
Founded 1891
Employees 75,000
Stock Exchange Toronto Stock Exchange
Ticker Symbol MRK
Full Company Profile

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD Financial Statements